Today FarmPharma AB, the subsidiary of Double Bond Pharmaceutical AB, signed a collaboration agreement with Karolinska Institutet (Department of Medicine, Solna) to conduct a project of producing start material for FarmPharma products. The work is estimated to start immediately. The goal of the project is the large-scale testing of the production of InterferOX parts and the company’s other products in order to facilitate the transition to GMP production.

“We are happy to be able to collaborate with world’s class researchers to fuel the development of PharmPharma’s products”, comments Igor Lokot, the Chairman of FarmPharma.

More om FarmPharma: FarmPharma AB is a subsidiary of Double Bond Pharmaceutical. The company is active in the development and distribution of veterinary products, and their first product is for the prevention and treatment of bacterial and viral infections in cattle without the use of antibiotics. For more info: http://www.farmpharma.se/

Video presentation: https://youtu.be/e1cPSC2PC70

This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 9 of December 2019.

____________________________________________________________________

Full Company Name:   Double Bond Pharmaceutical International AB (publ)

Corporate identity:       556991-6082

Stock short name:       DBP B

Share ISIN code:          SE0007185525

For more info, contact

Igor Lokot, CEO

Homepage: http://www.doublebp.com/

E-mail: info@doublebp.com

Blog: http://blog.doublebp.com

Follow us on LinkedIn (https://www.linkedin.com/company/double-bond-pharmaceutical?trk=co-feed-likes-one) and Twitter (https://twitter.com/DoubleBondPharm)!

_______________________________________________________________________________

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.